ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Abstract

The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (Aβ), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less.

1 - 71 . (canceled) 
     
     
         72 . A method for treating Alzheimer's disease (Aβ) in a human patient in need thereof comprising administering to the patient more than one 10 mg/kg dose of an anti-N3pGlu Aβ antibody over a period of 6 months or less wherein the antibody has a light chain of SEQ ID NO: 28 and a heavy chain of SEQ ID NO: 29. 
     
     
         73 . The method of  claim 72 , wherein the patient is suffering from preclinical AD, prodromal AD, mild AD, moderate Aβ, or severe AD. 
     
     
         74 . The method of  claim 73 , wherein the patient is suffering from preclinical AD. 
     
     
         75 . The method of  claim 73 , wherein the patient is suffering from prodromal AD. 
     
     
         76 . The method of  claim 72 , wherein the patient carries one or two APOE e4 alleles. 
     
     
         77 . The method of  claim 72 , wherein 3-5 doses of the anti-N3pGlu Aβ antibody are administered to the patient over a period of 6 months or less. 
     
     
         78 . The method of  claim 77 , wherein 3 doses of the anti-N3pGlu Aβ antibody are administered to the patient. 
     
     
         79 . The method of  claim 77 , wherein 4 doses of the anti-N3pGlu Aβ antibody are administered to the patient. 
     
     
         80 . The method of  claim 77 , wherein 5 doses of the anti-N3pGlu Aβ antibody are administered to the patient. 
     
     
         81 . The method of  claim 72 , wherein each 10 mg/kg dose of the anti-N3pGlu Aβ antibody is administered once every month. 
     
     
         82 . The method of  claim 72 , wherein each 10 mg/kg dose of the anti-N3pGlu Aβ antibody is administered to the patient once every 4 weeks. 
     
     
         83 . The method of  claim 72 , wherein each dose of the anti-N3pGlu Aβ antibody is administered intravenously to the patient. 
     
     
         84 . The method of  claim 72 , wherein administration of the anti-N3pGlu Aβ antibody causes reduction in Aβ deposits in the brain of the patient. 
     
     
         85 . The method of  claim 72 , wherein administration of the anti-N3pGlu Aβ antibody causes slowing of cognitive decline in the patient. 
     
     
         86 . The method of  claim 72 , wherein the Aβ deposits in the brain of the patient are reduced by 35-100% within 6 months post treatment. 
     
     
         87 . The method of  claim 72 , wherein 40-50% mean reduction in Aβ deposits in the brain of the patient is achieved over 6 months post treatment. 
     
     
         88 . The method of  claim 72 , wherein the reduction of Aβ deposits in the brain of the patient is sustained for a period of 2 to 10 years post treatment. 
     
     
         89 . The method of  claim 88 , wherein the reduction of Aβ deposits in the brain of the patient is sustained for a period of 3 to 5 years post treatment. 
     
     
         90 . The method of  claim 72 , wherein the reduction of Aβ deposits in the brain of the patient is sustained for a period of at least 18 months after the last dose of the anti-N3pGlu Aβ antibody. 
     
     
         91 . The method of  claim 72 , wherein the patients do not suffer from cerebral vasogenic edema or microhemorrhage upon administration of the anti-N3pGlu Aβ antibody.